ArticleThe world journal of men's health2026
Comparative Trends in the Treatment of Male Lower Urinary Tract Symptoms in South Korea and the United States of America (USA) Based on Korean National Health Insurance Data.
Article in The world journal of men's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWith increasing life expectancy worldwide, many patients experience non-life-threatening yet debilitating conditions that affect their quality of life. Among these, lower urinary tract symptoms, a representative urologic disease in men, continue to affect a significant number of aging males in the era of population aging. South Korea and the United States have distinct healthcare systems with notable advantages and limitations. This article aimed to analyze current treatment trends in South Korea using the National Health Insurance Database and compare them with United States trends through literature reviews. MATERIALS AND
methodsWe obtained statistical medical data using the Korean Healthcare Big Data Opening System provided by the Korea Health Insurance Review and Assessment Service. Data were collected across four categories: medical treatment for benign prostatic hyperplasia (BPH), surgical treatment for BPH, overactive bladder (OAB), and nocturia. The collected data were analyzed based on annual patient cases, medical expenses, age distribution, and prescribed medications.
resultsMedical expenses for BPH surged significantly from $165 million in 2019 to $266 million in 2023. Although medication prescriptions followed a similar upward trend, the increase in surgical procedures was relatively modest. For OAB, medical costs have also shown a sharp rise, from $40 million in 2019 to $59 million in 2023, with a proportional increase in prescription volume. Regarding nocturia, anticholinergics (32.7%) and alpha-blockers (31.3%) were the most frequently prescribed medications, whereas desmopressin accounted for 19.9%.
conclusionsIt is essential to acknowledge the treatment disparities arising from differences in the healthcare systems of the United States and Korea and to adopt a patient-centered approach that prioritizes health in various contexts. A gradual transition toward developing a patient-centered and progressive healthcare system is imperative globally to address these disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.